CHINA REGENERATIVE MEDICINE INTERNATIONAL LIMITED China Regenerative Medicine International Limited Share Price
Equities
8158
KYG2129W1380
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.27 HKD | 0.00% |
|
-3.57% | -50.91% |
| Sales 2021 | 283M 36.14M 2.89B | Sales 2022 | 232M 29.59M 2.37B | Capitalization | 317M 40.47M 3.24B |
|---|---|---|---|---|---|
| Net income 2021 | 13M 1.66M 133M | Net income 2022 | 4M 511K 40.91M | EV / Sales 2021 | 2.92 x |
| Net Debt 2021 | 25.9M 3.31M 265M | Net Debt 2022 | 70.16M 8.96M 718M | EV / Sales 2022 | 1.67 x |
| P/E ratio 2021 |
59.9
x | P/E ratio 2022 |
69.6
x | Employees | 46 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 37.05% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -3.57% | ||
| Current month | -6.90% | ||
| 1 month | -6.90% | ||
| 3 months | -49.06% | ||
| 6 months | -50.91% | ||
| Current year | -50.91% |
1 week
0.27
0.28
1 month
0.270.29
Current year
0.270.94
1 year
0.271.20
3 years
0.275.70
5 years
0.279.00
10 years
0.27200.00
| Managers | Title | Age | Since |
|---|---|---|---|
Chuang Wang
CEO | Chief Executive Officer | 45 | 17/10/19 |
Po Tin Wong
DFI | Director of Finance/CFO | 47 | 31/08/22 |
Jinnan Zhang
CTO | Chief Tech/Sci/R&D Officer | 39 | 02/09/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Man Fai Leung
BRD | Director/Board Member | 66 | 29/12/21 |
Ho Yin Tsang
BRD | Director/Board Member | 39 | 29/01/20 |
Chuang Wang
CEO | Chief Executive Officer | 45 | 17/10/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.27 | 0.00% | 0 |
| 25/04/24 | 0.27 | -3.57% | 0 |
| 24/04/24 | 0.28 | 0.00% | 0 |
| 23/04/24 | 0.28 | 0.00% | 0 |
| 22/04/24 | 0.28 | 0.00% | 0 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotes
China Regenerative Medicine International Ltd is an investment holding company mainly engaged in the provision of comprehensive health products and services. The Company is engaged in the supply and sale of medical products and medical equipment. In addition, the Company is engaged in the provision of various health management services such as health assessment, detoxification treatment, homeostasis, organ maintenance and immune system enhancement.
Calendar
09/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -50.91% | 10.49M | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- 8158 Stock
